← Back to Search

Behavioural Intervention

Transmagnetic Stimulation for Primary Progressive Aphasia (TMS in PPA Trial)

N/A

Waitlist Available

Led By Michael H Rosenbloom, MD

Research Sponsored by HealthPartners Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subjects are between 40-90 years of age

Be older than 18 years old

Must not have

Seizure disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial studies a non-invasive therapy for Frontotemporal Degeneration (FTD), a type of dementia, using brain scans and magnetic stimulation. The goal is to improve symptoms and support current treatment.

Who is the study for?

This trial is for individuals aged 40-90 with a confirmed diagnosis of nonfluent/agrammatic or semantic variant primary progressive aphasia. They must have had prior brain imaging and a Mini Mental Status Exam score over 10. Those with other types of dementia, seizure disorders, or who can't undergo fMRI due to implants/metal are excluded.

What is being tested?

The study tests intermittent theta burst stimulation (iTBS), a non-invasive treatment using transcranial magnetic stimulation aimed at improving language functions in people with primary progressive aphasia by targeting specific brain regions.

What are the potential side effects?

While the description doesn't list side effects, iTBS is generally considered safe but may cause discomfort at the stimulation site, headache, lightheadedness, or temporary hearing changes during the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 40 and 90 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a seizure disorder.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Connectivity measures of the left TGd, 55b, and STV parcellations at baseline and post-treatment

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Intermittent theta burst stimulationExperimental Treatment1 Intervention

All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 8-10 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Intermittent theta burst stimulation

2022

Completed Phase 2

~160

0 / 2Eligibility criteria met